In the late 1990s ACADIA scientists* started achemical genomics...

In the late 1990s ACADIA scientists* started achemical genomics effort aimed at improving the understanding of the targetsfor drugs acting on the central nervous system. They discovered and developed anovel drug to treat Parkinson’s Psychosis they called Pimavanserin. This is made and marketed by Acadia as Nuplazid. (See Neurochem Res. 2014; 39(10): 2008–2017). The pimavanserin-specific patent and the Parkinson's diseasepsychosis treatment patent provide protection until June 2027 and 2026, respectively. The patent that coverspolymorphs of pimavanserin provides protection until June 2028.

In the pharmaceutical industry, manufacturersof generic drugs seek to capitalise on the success of 1^st world companieslike ACADIA and their brilliant scientists, by making generic copies of successful drugs like Nuplazid.

The US market’s reaction to a negative patent-rulingis understandable but the ruling is not fatal. I view ACADIA’s experience andsuccess with Nuplazid in particular as being hugely advantageous for developingNEUREN’s portfolio of drug candidates. These future prospects are where we should be focussing our attention.

*(PS check out : Uli Hacksell, Ethan S. Burstein, Krista McFarland, Roger G. Mills, and Hilde Williams)

Not professionaladvice : please do your own DD